R
Robert J. Motzer
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 969
Citations - 95706
Robert J. Motzer is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 121, co-authored 883 publications receiving 80129 citations. Previous affiliations of Robert J. Motzer include Cleveland Clinic & Kettering University.
Papers
More filters
Journal ArticleDOI
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Robert J. Motzer,Thomas E. Hutson,Piotr Tomczak,M. Dror Michaelson,Ronald M. Bukowski,Olivier Rixe,Stéphane Oudard,Sylvie Negrier,Cezary Szczylik,Sindy T. Kim,Isan Chen,Paul Bycott,Charles M. Baum,Robert A. Figlin +13 more
TL;DR: Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa.
Journal ArticleDOI
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Bernard Escudier,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Toni K. Choueiri,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Yoshihiko Tomita,Fabio A.B. Schutz,Christian Kollmannsberger,James Larkin,Alain Ravaud,Jason S. Simon,Li-an Xu,Ian M. Waxman,Padmanee Sharma +26 more
TL;DR: Overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus among patients with previously treated advanced renal-cell carcinoma.
Journal ArticleDOI
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Gary R. Hudes,Michael A. Carducci,Piotr Tomczak,Janice P. Dutcher,Robert A. Figlin,Anil Kapoor,Elzbieta Staroslawska,Jeffrey A. Sosman,David F. McDermott,Istvan Bodrogi,Zoran Kovacevic,Vladimir Lesovoy,Ingo G.H. Schmidt-Wolf,Olga Barbarash,Erhan Gokmen,Timothy O'Toole,Stephanie Lustgarten,Laurence Moore,Robert J. Motzer +18 more
TL;DR: As compared with interferon alfa, temsirolimus improved overall survival among patients with metastatic renal-cell carcinoma and a poor prognosis.
Journal ArticleDOI
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Nizar M. Tannir,David F. McDermott,Osvaldo Arén Frontera,Bohuslav Melichar,Toni K. Choueiri,Elizabeth R. Plimack,Philippe Barthélémy,Camillo Porta,Saby George,Thomas Powles,Frede Donskov,V. Neiman,V. Neiman,Christian Kollmannsberger,Pamela Salman,Howard Gurney,Robert E. Hawkins,Alain Ravaud,Marc-Oliver Grimm,Sergio Bracarda,Carlos H. Barrios,Yoshihiko Tomita,Daniel Castellano,Brian I. Rini,Allen C. Chen,Sabeen Mekan,M. Brent McHenry,Megan Wind-Rotolo,Justin Doan,Padmanee Sharma,Hans J. Hammers,Hans J. Hammers,Bernard Escudier +33 more
TL;DR: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate‐ and poor‐risk patients with previously untreated advanced renal‐cell carcinoma.
Journal ArticleDOI
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer,Bernard Escudier,Stéphane Oudard,Thomas E. Hutson,Camillo Porta,Sergio Bracarda,Viktor Grünwald,John A. Thompson,Robert A. Figlin,Norbert Hollaender,Gladys Urbanowitz,William Berg,Andrea Kay,David Lebwohl,Alain Ravaud +14 more
TL;DR: Treatment with everolimus prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma that had progressed on other targeted therapies, but were mostly mild or moderate in severity.